Reply to von Bünau et al. Comment on “Depoorter, L.; Vandenplas, Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021, 13, 2176”
KidZ Health Castle, UZ Brussel, Vrije Universiteit Brussel, 1090 Brussels, Belgium
*
Author to whom correspondence should be addressed.
Nutrients 2022, 14(4), 725; https://doi.org/10.3390/nu14040725
Submission received: 5 January 2022
/
Accepted: 11 January 2022
/
Published: 9 February 2022
(This article belongs to the Special Issue Nutritional Habits and Interventions in Childhood)
We agree with Prof. Stange and Erhardt for their comment on our paper on Probiotics in Pediatrics [1], regarding our statement “In adults, several studies showed a beneficial effect of E. coli Nissle 1917 compared to standard treatment with mesalazine alone in maintaining remission of the disease [1,2]. Again, these results were not confirmed by any RCT [3].” As Prof. Stange and Erhardt claim, we reported that there are trials with E. coli Nissle 1917 in adults. However, there are—to the best of our knowledge—no randomized controlled trials in children. Therefore, we wrote “Again, these studies were not confirmed by any randomized controlled trial” (in children, since the manuscript is about probiotics in pediatrics). So, while there is some evidence in adults, there are no data in pediatrics.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Depoorter, L.; Vandenplas, Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021, 13, 2176. [Google Scholar] [CrossRef] [PubMed]
- Scaldaferri, F.; Gerardi, V.; Mangiola, F.; Lopetuso, L.R.; Pizzoferrato, M.; Petito, V.; Papa, A.; Stojanovic, J.; Poscia, A.; Cammarota, G.; et al. Role and Mechanisms of Action of Escherichia coli Nissle 1917 in the Maintenance of Remission in Ulcerative Colitis Patients: An Update. World J. Gastroenterol. 2016, 22, 5505–5511. [Google Scholar] [CrossRef] [PubMed]
- Petersen, A.M.; Mirsepasi, H.; Halkjær, S.I.; Mortensen, E.M.; Nordgaard-Lassen, I.; Krogfelt, K.A. Ciprofloxacin and Probiotic Escherichia coli Nissle Add-on Treatment in Active Ulcerative Colitis: A Double-Blind Randomized Placebo Controlled Clinical Trial. J. Crohn’s Colitis 2014, 8, 1498–1505. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Vandenplas, Y.; Depoorter, L. Reply to von Bünau et al. Comment on “Depoorter, L.; Vandenplas, Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021, 13, 2176”. Nutrients 2022, 14, 725. https://doi.org/10.3390/nu14040725
AMA Style
Vandenplas Y, Depoorter L. Reply to von Bünau et al. Comment on “Depoorter, L.; Vandenplas, Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021, 13, 2176”. Nutrients. 2022; 14(4):725. https://doi.org/10.3390/nu14040725
Chicago/Turabian StyleVandenplas, Yvan, and Leontien Depoorter. 2022. "Reply to von Bünau et al. Comment on “Depoorter, L.; Vandenplas, Y. Probiotics in Pediatrics. A Review and Practical Guide. Nutrients 2021, 13, 2176”" Nutrients 14, no. 4: 725. https://doi.org/10.3390/nu14040725
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
